GREY:TSTIF - Post by User
Post by
bossuon Oct 05, 2016 9:33am
187 Views
Post# 25310875
From this morning Globe&Mail
From this morning Globe&Mail
lobe says TSO3 targeted at $5
2016-10-05 07:57 ET - In the News
Shares issued 91,943,881
TOS Close 2016-10-04 C$ 3.27
The Globe and Mail reports in its Wednesday edition that Nick Agostino believes health-care tech company TSO3 has upside potential. The Globe's Jennifer Dowty writes that the Laurentian Bank analyst targets TSO3, now $3.27, at $5. Mr. Agostino bestows TSO3 the current technology accolades, boasting "game-changing, disruptive technology" for the low-temperature sterilization market. The company went through a long process with the U.S. Food and Drug Administration but comes out of it in great standing, with: 1) full FDA approvals including for the endoscopic market; 2) its own FDA classification and numerous patents; 3) the ability to provide a high-throughput cost-saving product for hospitals; and 4) a five-year exclusive global-distribution agreement with industry leader Getinge Group. Over all, Mr. Agostino says he tries to focus his investment decisions on a few themes: companies that have strong market fundamentals, competitive advantages for sustainability, revenue predictability and solid cash-flow generatio -- and health-care equipment and software companies that should benefit from an aging population and are able to improve health-care systems in North America.